According to a major recent study, appearing in the July 27 issue of the "Journal of Clinical Oncology," there is a definite downstaging trend for prostate cancer. The study, which surveyed almost 13,000 American men who had a radical prostatectomy (surgical removal of a cancerous prostate gland) between 1987 and 2005, found that only 12% of them died of the cancer. This is great news, according…
The first joint congress ECCO 15 - ESMO 34 of the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) is taking place this week in Berlin. It is the only congress in Europe that covers the entire spectrum of cancer from basic science and translational research, to prevention, treatment, nursing and supportive care for all types of tumours.
A new initiative designed to inform and educate policymakers at national, European, and global level about the needs of the oncology community was launched at Europe's largest cancer congress, ECCO 15 — ESMO 34, in Berlin. The European Academy of Cancer Sciences will help to keep the interests of cancer patients at the forefront of the policy agenda, and avoid policy decisions that had a…
Dresden, Germany 16-19 September
3D Net Perfusion, new software developed by The Institute of Cancer Research (ICR) working with Biotronics3D, aims to improve the accuracy of MRI scan analysis and treatment efficacy by extracting data from tumour images and transforming it into usable information. In addition, the analytical tool provides a method to visualise and measure blood supply to cancers - a crucial factor in tumour…
Emphasising the crucial partnership of radiologists and urologists in the treatment of prostate cancer, Professor Arnulf Stenzl, Medical Director of Urology at the Tübingen University Hospital, explained that, throughout the phases of prostate cancer diagnosis and therapy - from primary diagnosis onward - imaging is indispensable.
During a gathering of clinicians, scientists and economists at this year's Medical Technology Congress (Treffpunkt für Medizintechnik) held in Berlin's Charité Hospital, all 17 lectures focused on cancer treatments. Bettina Döbereiner reports
Munich, Germany 6 - 10 October
Positive CB7630 (Abiraterone Acetate) Phase II Data was presented at the ASCO Annual Meeting in Chicago this May/June, Cougar Biotechnology Inc, a development stage biopharmaceutical firm with a specific focus on oncology. In mid-July, Johnson & Johnson announced its acquisition of Cougar, which is now working with Ortho Biotech Oncology Research & Development, a division of the J&J firm Centocor…
Completion of a Phase I clinical trial has demonstrated the great promise of a completely new type of cancer treatment, according to results announced this June in The New England Journal of Medicine by scientists at the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in the United Kingdom, working with pharma firm AstraZeneca.
Barcelona, Spain 26-29 November
PSA-Kritiker PD Dr. rer. nat. Hans-Hermann Dubben und DGU-Generalsekretär Prof. Dr. Michael Stöckle suchten das Gespräch Selten wurde zwischen den Kritikern und den Befürwortern der PSA-gestützten Früherkennung des Prostatakarzinoms so hart diskutiert. Die Veröffentlichung der randomisierten Studien zum PSA-Screening aus Europa (ERSPC-Studie) und den USA (PLCO-Screeningstudie) hatte in…
IMRT is an evolving method of treatment for complex forms of cancer. Although patients benefit from treatment, a precise evaluation of that benefit and overall cost-effectiveness of the method is still an uncertain science. Mark Nicholls reports
Tissue removal is currently the only way to verify suspicious lesions in the prostate. It is also a key requirement before treating prostate carcinomas. The standard biopsy is performed with transrectal ultrasound (TRUS) to guide the needle in the right direction.
Training is critical to the further development of urology across Europe, yet urologists recognise there are gaps in this; so much so that the European Society of Urological Technology (ESUT) has restructured with an emphasis on training to meet the demands and challenges ahead. Mark Nicholls reports.
To date, there is insufficient knowledge as to the cause of this disease, or how to prevent it. We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
Big discussions are expected at the upcoming European Association of Urology (EAU) Congress in Stockholm* when urologist Dr Jochen Walz (right), of the Urological Department at the Institute Paoli-Calmettes, Marseilles, France, presents the forum: Imaging in Europe: Who, where, what, how many! and M F Coelho, of the European Society of Urological Imaging (ESUI) describes the Clinical utility of…
A potential biomarker for cancer has been identified in urine.
Accreditation and standards of Excellence in Europe
To date, there is insufficient knowledge as to the cause of this disease, or how to prevent it. We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
The number of prostate cancer cases is increasing rapidly.
GE Healthcare's first Discovery PET/CT 600-series scanners are being installed in a number of leading clinics around the world. "This first set of installations is a big step forward in the diagnosis and monitoring of disease", said Terri Bresenham, newly appointed vice- president and general manager of GE Healthcare's global Molecular Imaging business.
17-21 March Stockholm Sweden
We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
Current procedures are still imprecise and speculative; without a subsequent biopsy suspicious PSA levels, images and the results of palpation cannot be correctly evaluated. Thus there is an energetic pursuit to discover new imaging technologies. Dr Thilo Eggert at the Urological Clinic of the Ruhr University Bochum at the Marienhopital Herne, is among the investigators.
